ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1996

Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 0442

Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Abstract Number: 0241

Inequity in Disease Impact Between Male and Female Rheumatoid Arthritis Patients
Abstract Number: 0384

Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study
Abstract Number: 1290

Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage and Patient Distress Are as Prominent in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist
Abstract Number: 1399

Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis
Abstract Number: 2166

Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments
Abstract Number: 0651

Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis
Abstract Number: 0721

Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex
Abstract Number: 0245

Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Abstract Number: 2174

Influence of Immunosuppressive Therapy on Gastrointestinal Symptoms in Patients with Systemic Sclerosis
Abstract Number: 0970

Influence of Sociodemographic and Clinical Features on Ground Reaction Force Variability Among Individuals with Symptomatic Knee Osteoarthritis: A Novel Computational Approach
Abstract Number: L16

Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)
Abstract Number: 0678

Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019
Abstract Number: 1758

Intake of Dairy Products as a Risk Factor for Rheumatoid Arthritis; A Nested Case-Control Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].